Compare SIG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIG | ERAS |
|---|---|---|
| Founded | 1950 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | 1997 | 2021 |
| Metric | SIG | ERAS |
|---|---|---|
| Price | $86.74 | $15.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $111.14 | $14.25 |
| AVG Volume (30 Days) | 933.1K | ★ 5.4M |
| Earning Date | 06-02-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 974.07 | 36.23 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $6,247,100,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $1.71 | N/A |
| P/E Ratio | $107.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $71.62 | $1.24 |
| 52 Week High | $110.20 | $24.28 |
| Indicator | SIG | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 61.26 |
| Support Level | $81.23 | $14.00 |
| Resistance Level | $95.59 | $16.14 |
| Average True Range (ATR) | 4.01 | 1.00 |
| MACD | -0.28 | 0.19 |
| Stochastic Oscillator | 36.32 | 83.67 |
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.